DYAI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

DYAI ▲ +22.86% at T+20d

NEUTRAL call ✓ call won +22.86% · α vs SPY +12.19% · entry $0.7000 → $0.8600

Next anchor: T+60d in 7d

Last close $0.6800 (close Jun 12) · -2.86% from $0.7000 entry

Entry anchored
Mar 25, 03:59 PM ET
via Databento tick

T+1d

-2.86%

call -2.86% · α -1.18%

$0.6800

settled 3mo ago

T+5d

+27.14%

call +27.14% · α +25.51%

$0.8900

settled 3mo ago

T+20d

+22.86%

call +22.86% · α +12.19%

$0.8600

settled 8w ago

T+60d

—

call — · α —

—

in 7d

Price Chart

Loading chart...

Executive Summary

Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50 million in 2024, driven by lower license and milestone revenue. Despite cost reductions in G&A and R&D, the company's net loss widened to $7.36 million. However, the press release highlighted multiple new commercial partnerships and product launches across life sciences and nutrition markets, including the AlbuFree™ DX launch and expanded collaboration with Fermbox Bio.

Key Financial Metrics

Revenue

$3.1M

-11.7% YoY

EPS

$-0.23

Actionable Insight

Monitor upcoming product commercialization timelines (e.g., Inzymes' chymosin launch in 2026) and potential milestone payments. The growing partner network may support future revenue diversification, but near-term fundamentals remain weak.

Key Facts

Total revenue decreased to $3.09 million in 2025 from $3.50 million in 2024
License and milestone revenue dropped to $265,000 from $1.89 million in 2024
Grant revenue increased to $1.86 million in 2025 due to Gates Foundation and CEPI funding
Net loss widened to $7.36 million in 2025 from $5.81 million in 2024
Cash position declined to $8.59 million as of December 31, 2025, from $9.29 million in 2024
Commercial launch of AlbuFree™ DX with Proliant, OEM deal with IBT Bioservices, and new agreements with BRIG Bio and Inzymes announced

Financial Impact

Revenue down 11.7% YoY; net loss increased by $1.55 million; cash reserves down $700K

revenueepsnet_losscash

Risk Factors

Continued decline in core licensing and collaboration revenue
Reliance on future milestone and grant funding to offset operational losses
Cash burn trend with reserves below $9 million

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3262620

4 reports for DYAI

T+1T+5T+20T+60

Filters

Reports for DYAI — sortable, filterable
	Type				Now
May 28, 2026 17d ago	8-K NEUTRAL ★ 4/10	$0.7100 $0.7000	▼ −1.41%	▼ −1.36%	$0.6800 (−4.23%)
Mar 25, 2026 11w ago	Press Release MIXED ★ 5/10	$0.7000 $0.8900	▲ +27.14%	▲ +25.51%	$0.6800 (−2.86%)
Mar 16, 2026 13w ago	Press Release MIXED ★ 5/10	$0.8100 $0.8600	▲ +6.17%	▲ +8.21%	$0.6800 (−16.05%)
Mar 4, 2026 14w ago	Press Release NEUTRAL ★ 4/10	$0.8200 $0.8000	▼ −2.44%	▼ −1.11%	$0.6800 (−17.07%)

US Market Status

Market Closed — Opens in 2h 9m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access